MEDREGEN LLC
🇺🇸United States
MRG-001 in Patients With Amyotrophic Lateral Sclerosis
Phase 2
Not yet recruiting
- Conditions
- Amyotrophic Lateral SclerosisLou Gehrig DiseaseMotor Neuron DiseaseMotor Neuron Atrophy
- Interventions
- First Posted Date
- 2024-03-18
- Last Posted Date
- 2024-08-23
- Lead Sponsor
- MedRegen LLC
- Target Recruit Count
- 10
- Registration Number
- NCT06315608
MRG-001 as an Immunoregulatory and Regenerative Therapy for ARDS Patients
Phase 2
Not yet recruiting
- Conditions
- Cytokine StormAcute Respiratory Distress SyndromeRespiratory FailureRespiratory Distress SyndromeRespiratory Tract Diseases
- Interventions
- Drug: MRG-001 (High-dose)Other: PlaceboDrug: MRG-001 (Low-dose)
- First Posted Date
- 2024-03-13
- Last Posted Date
- 2024-08-23
- Lead Sponsor
- MedRegen LLC
- Target Recruit Count
- 60
- Registration Number
- NCT06308926
MRG-001 in Patients With Alcoholic Hepatitis
Phase 2
Not yet recruiting
- Conditions
- Acute Alcoholic HepatitisAlcoholic Hepatitis
- Interventions
- First Posted Date
- 2024-03-13
- Last Posted Date
- 2024-03-13
- Lead Sponsor
- MedRegen LLC
- Target Recruit Count
- 32
- Registration Number
- NCT06307522
Safety and Efficacy of MRG-001 in Wound Healing in Abdominoplasty Patients
- First Posted Date
- 2023-05-06
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- MedRegen LLC
- Target Recruit Count
- 10
- Registration Number
- NCT05844527
- Locations
- 🇺🇸
Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States
MRG-001 as an Immunoregulatory and Regenerative Therapy for COVID-19 Patients
- First Posted Date
- 2020-11-30
- Last Posted Date
- 2022-02-15
- Lead Sponsor
- MedRegen LLC
- Target Recruit Count
- 40
- Registration Number
- NCT04646603
- Locations
- 🇺🇸
Johns Hopkins Medicine, Baltimore, Maryland, United States
© Copyright 2025. All Rights Reserved by MedPath